The startup develops therapeutics that modulate the innate immune system to target chronic low-grade inflammation, a key factor in age-related cancer and inflammatory diseases. Their clinically validated approach enables healthcare professionals to effectively treat conditions such as age-related cancer and osteoarthritis.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic low-grade inflammation, driven by cellular aging mechanisms, is a significant underlying factor in age-related diseases, including cancer and osteoarthritis, and is a leading cause of death worldwide. Current therapeutic development often originates from cellular and animal models, leading to high attrition rates due to translational gaps.
Solution
Immetas is developing novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases by targeting chronic low-grade inflammation. The company's approach leverages clinical data from human genetic disorders and clinical trials to identify and validate relevant targets. By integrating clinical data at the front end of drug discovery, Immetas aims to mitigate development risk and accelerate the creation of superior, well-differentiated products. Their approach focuses on dissecting the mechanism of action of key molecular pathways driving cellular aging and age-related diseases, allowing for the design of targeted interventions.
Target Audience
The primary target audience includes individuals suffering from age-related cancers and inflammatory diseases, particularly osteoarthritis, as well as healthcare professionals seeking effective treatments for these conditions.
Features
- Focus on modulating the innate immune system to address chronic inflammation.
- Development of both small and large molecule therapeutics.
- Targets key cell types in the tumor microenvironment, such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs).
- Utilizes bispecific antibody (BiSAb) formats to target multiple antigens simultaneously.
- Intra-articular injection of compounds to target synovial inflammation in osteoarthritis.